icon-folder.gif   Conference Reports for NATAP  
  65th Annual Meeting of the
American Association for the
Study of Liver Diseases
Boston, MA Nov 7-11 2014
Back grey_arrow_rt.gif
The Pharmacokinetics of Ledipasvir, an HCV-Specific NS5A Inhibitor, in HCV-Uninfected Subjects With Severe Renal Impairment
  Reported by Jules Levin
AASLD 2014 Nov 7-11 Boston
Erik Mogalian,1 Anita Mathias,1 Jenny Yang,1 Lisa Moorehead,1 Maria Hernandez,1 Kenneth Lasseter,2 Daniel K. Ries,3 Richard A. Robson,4 Gemot K. Klein5 1Gilead Sciences, Inc., Foster City, CA; 2Clinical Pharmacology of Miami, Inc., Miami, FL; 3Prism Clinical Research, St Paul, MN; 4Christchurch Clinical Studies Trust, Ltd, Christchurch, New Zealand; 5APEX GmbH, Bremen, Germany